Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice-Reference-Cited by-同舟云学术

Prospective Assessment of No Evidence of Disease Activity-4 Status in Early Disease Stages of Multiple Sclerosis in Routine Clinical Practice

Published:2019-07-24 Issue: Volume:10 Page:
ISSN:1664-2295
Container-title:Frontiers in Neurology
language:
Short-container-title:Front. Neurol.

Author:

Guevara Carlos,Garrido Cristian,Martinez Melissa,Farias Gonzalo A.,Orellana Patricia,Soruco Wendy,Alarcón Pablo,Diaz Violeta,Silva Carlos,Kempton Matthew J.,Barker Gareth,de Grazia José

Publisher

Frontiers Media SA

Subject

Clinical Neurology,Neurology

Reference34 articles.

1. Editors' welcome and a working definition for a multiple sclerosis cure;Banwell;Mult Scler Relat Disord.,2013

2. An epidemiological study on the course of disease and therapeutic considerations in relapsing-remitting multiple sclerosis patients receiving injectable first-line disease-modifying therapies in Germany (EPIDEM);Schmidt;Therap Adv Neurol Disord,2018

3. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis;Smith;NeuroImage,2002

4. Normalized accurate measurement of longitudinal brain change;Smith;J Comput Assist Tomogr,2001

5. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis;Kappos;Multi Scler,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing disease progression and treatment response in progressive multiple sclerosis;Nature Reviews Neurology;2024-09-09

2. Multiple sclerosis: modern diagnostic markers and prognostic factors of disease progression;Сибирский научный медицинский журнал;2024-03-06

3. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder;Scientific Reports;2024-02-12

4. Brain volume loss in relapsing multiple sclerosis: Indirect treatment comparisons of available disease-modifying therapies;2023-11-20

5. Prevalence of 2-year “No evidence of disease activity” (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study;Multiple Sclerosis and Related Disorders;2023-11